Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sgp(schering plough) -- Ignore unavailable to you. Want to Upgrade?

To: alruss who wrote (106)	5/1/2000 3:24:00 PM
From: Neil H	Respond to of 117

Monday May 1, 1:09 pm Eastern Time Schering says Peg-Intron more effective than Intron A NEW YORK, May 1 (Reuters) - Pharmaceutical firm Schering-Plough Corp. (NYSE:SGP - news) said on Monday that results of a Phase III clinical study showed that a once-a-week injection of Peg-Intron is more effective than an Intron A injection given three times per week in treating hepatitis C. The test results, presented in the Netherlands at the 35th Annual Meeting of the European Association for the Study of the Liver, showed that patients treated with Peg-Intron achieved significantly greater loss of detectable hepatitis C virus during treatment, at the end of treatment and at the end of follow-up, compared to patients treated with Intron A, the company said. The study also concluded that Peg-Intron is as safe as Intron A. Peg-Intron is a longer-acting form of Intron A that uses proprietary technology developed by Enzon Inc. (NasdaqNM:ENZN - news). Madison, N.J.-based Schering-Plough holds an exclusive worldwide license to Peg-Intron. The randomized, controlled Phase III study was designed to establish the safety and efficacy of Peg-Intron versus Intron A monotherapy in adult patients with previously untreated chronic hepatitis C and compensated liver disease. Shares of Schering-Plough were up 12/16 at 41-1/16 on the New York Stock Exchange. Enzon shares rose 1-7/16 to 38-7/16.